NCT02969187View on ClinicalTrials.gov

Bupivacaine Liposomal Injection (Exparel) for Postsurgical Analgesia in Patient Undergoing Laparoscopic Bariatric Surgery

PHASE4CompletedINTERVENTIONAL
Enrollment

126

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

January 31, 2018

Study Completion Date

March 31, 2018

Conditions
Pain, Postoperative
Interventions
DRUG

Exparel

6 trocars are placed to perform LRYGB or LSG: two 12 mm trocars and four 5 mm trocars. Exparel will be injected at port sites.

DRUG

Bupivacain

6 trocars are placed to perform LRYGB or LSG: two 12 mm trocars and four 5 mm trocars. Bupivacain will be injected at port sites.

DRUG

Saline

Trial Locations (1)

44195

Cleveland Clinic, Cleveland

All Listed Sponsors
lead

The Cleveland Clinic

OTHER

NCT02969187 - Bupivacaine Liposomal Injection (Exparel) for Postsurgical Analgesia in Patient Undergoing Laparoscopic Bariatric Surgery | Biotech Hunter | Biotech Hunter